Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nathanson

Showing results (201-210 of 528) with videos related to

Pageof 53
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 20, 2017
Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African AncestryShengfeng Wang, Yonglan Zheng, Temidayo O Ogundiran, et al.
Endocrine-Related Cancer|June 2, 2017
<i>SDHB</i> mutation carriers with malignant pheochromocytoma respond better to CVDL Fishbein, S Ben-Maimon, S Keefe, et al.
Genetic Testing|April 1, 2008
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutationsEsme Finlay, Jill E Stopfer, Eric Burlingame, et al.
Familial Cancer|March 3, 2011
PALB2 mutations in familial breast and pancreatic cancerErin W Hofstatter, Susan M Domchek, Alexander Miron, et al.
International Journal of Radiation Oncology, Biology, Physics|September 1, 1979
Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hpydroxyurea and vincristine in the treatment of malignant gliomaM Costanza, M Buechler, J Munzenreider, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responsesJessica A Bertout, Amar J Majmundar, John D Gordan, et al.
Journal of Medical Genetics|December 19, 2001
Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1C Eng, L C Brody, T M Wagner, et al.
JAMA Network Open|February 18, 2025
Pathogenic Germline Variants in Patients With Metaplastic Breast CancerKaitlin Demarest, Arravinth Anantharajah, Kara N Maxwell, et al.
Cancer Research|August 16, 2008
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer familiesMaurizia Dalla Palma, Susan M Domchek, Jill Stopfer, et al.
American Journal of Human Genetics|September 9, 2000
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencingM A Unger, K L Nathanson, K Calzone, et al.
Pageof 53

Showing results (201-210 of 528) with videos related to

Sort By:
Pageof 53
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 20, 2017
Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African AncestryShengfeng Wang, Yonglan Zheng, Temidayo O Ogundiran, et al.
Endocrine-Related Cancer|June 2, 2017
<i>SDHB</i> mutation carriers with malignant pheochromocytoma respond better to CVDL Fishbein, S Ben-Maimon, S Keefe, et al.
Genetic Testing|April 1, 2008
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutationsEsme Finlay, Jill E Stopfer, Eric Burlingame, et al.
Familial Cancer|March 3, 2011
PALB2 mutations in familial breast and pancreatic cancerErin W Hofstatter, Susan M Domchek, Alexander Miron, et al.
International Journal of Radiation Oncology, Biology, Physics|September 1, 1979
Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hpydroxyurea and vincristine in the treatment of malignant gliomaM Costanza, M Buechler, J Munzenreider, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2009
HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responsesJessica A Bertout, Amar J Majmundar, John D Gordan, et al.
Journal of Medical Genetics|December 19, 2001
Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1C Eng, L C Brody, T M Wagner, et al.
JAMA Network Open|February 18, 2025
Pathogenic Germline Variants in Patients With Metaplastic Breast CancerKaitlin Demarest, Arravinth Anantharajah, Kara N Maxwell, et al.
Cancer Research|August 16, 2008
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer familiesMaurizia Dalla Palma, Susan M Domchek, Jill Stopfer, et al.
American Journal of Human Genetics|September 9, 2000
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencingM A Unger, K L Nathanson, K Calzone, et al.
Pageof 53